Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-02-29
1998-04-21
Lambkin, Deborah
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514443, 514461, 514469, 549 58, 549 78, 549 79, 549445, 549454, A61K 3138, A61K 3134, C07D33306, C07D31704
Patent
active
057418101
ABSTRACT:
The present invention provides to cyclopentane heptanoic acid, 2 heteroaryl alkyl or alkenyl derivatives which may be substituted in the 1-position with hydroxyl, alkyloxy, amino and amido groups, e.g. 1-OH cyclopentane heptanoic acid, 2 heteroarylalkenyl derivatives. In particular, these hydroxyhydrocarbyl)-3-hydroxycyclopentyl!heptanoic or heptenoic acids and amine, amide, ether, ester and alchohol derivatives of said acids wherein one or more of said hydroxy groups are replaced with an ether group. These compounds are potent ocular hypotensive and are particularly suited for the management of glaucoma. Moreover, the compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; with additional application in gastrointestinal disease, reproduction, fertility, incontinence, shock, inflammation, immune regulation, disorder of bone metabolism, renal dysfunction, cancer and other hypoproliferative diseases.
REFERENCES:
patent: 3845115 (1974-10-01), Lincoln, Jr. et al.
patent: 4560786 (1985-12-01), Skuballa et al.
patent: 4585791 (1986-04-01), Faustini et al.
patent: 4994274 (1991-02-01), Chan et al.
patent: 5028624 (1991-07-01), Chan et al.
patent: 5034413 (1991-07-01), Chan et al.
patent: 5321128 (1994-06-01), Stjernschantz et al.
patent: 5446041 (1995-08-01), Chan et al.
patent: 5545665 (1996-08-01), Burk
Greene, T.W., "Protective Groups in Organic Synthesis", pp. 10-16, 1981.
Bito, L.Z., "Prostaglandins and Related Compounds as Potential Ocular Therapeutic Agents," Biological Protection with Prostaglandins, Cohen, M.M., ed., Boca Raton, Fla, CRC Press, Inc., 1985, pp. 231-252.
Bito, L.Z., "Prostaglandins, Other Eicosanoids, and Their Derivatives as Potential Antiglaucoma Agents,"0 Applied Pharmacology in the Medical Treatment of Glaucomas Drance, S.M. and Neufeld, A.H. eds., New York, Grune & Stratton, 1984, pp. 477-505.
Nilsson, et.al., "PGF.sub.2.alpha. Increases Uveoscleral Outflow," Invest. Ophthalmol. Vis. Sci. (suppl), 284, 1987.
Siebold, et.al., "Esterified prostaglandin shows `potent` promise," Prodrug 5 3, 1989.
Bito, L.Z., "Prostaglandins, Old Concepts and New Perspectives," Arch. Ophthalmol. 105, 1036, 1987.
Allergan
Baran Robert J.
Lambert Howard R.
Lambkin Deborah
Voet Martin A.
LandOfFree
Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivati does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivati, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivati will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2057823